[go: up one dir, main page]

MA37836A1 - 5-HT3 Receptor Antagonists - Google Patents

5-HT3 Receptor Antagonists

Info

Publication number
MA37836A1
MA37836A1 MA37836A MA37836A MA37836A1 MA 37836 A1 MA37836 A1 MA 37836A1 MA 37836 A MA37836 A MA 37836A MA 37836 A MA37836 A MA 37836A MA 37836 A1 MA37836 A1 MA 37836A1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
disorders
compounds
present
receptor
Prior art date
Application number
MA37836A
Other languages
French (fr)
Other versions
MA37836B1 (en
Inventor
Stephen Hitchcock
Holger Monenschein
Holly Reichard
Huikai Sun
Shota Kikuchi
Todd Macklin
Maria Hopkins
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Priority claimed from PCT/US2013/050746 external-priority patent/WO2014014951A1/en
Publication of MA37836A1 publication Critical patent/MA37836A1/en
Publication of MA37836B1 publication Critical patent/MA37836B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des antagonistes du récepteur 5-ht3 de formule (i) qui sont utiles pour le traitement de maladies pouvant être traitées par l'inhibition du récepteur 5-ht3, tels que le vomissement, la douleur, la pharmacodépendance, les troubles neurodégénératifs et psychiatriques, et les troubles gastro-intestinaux. La présente invention concerne en outre des compositions pharmaceutiques contenant de tels composés et des procédés pour préparer de tels composés.The present invention relates to 5-HT 3 receptor antagonists of formula (i) which are useful for the treatment of diseases that can be treated by inhibition of the 5-HT 3 receptor, such as vomiting, pain, drug dependence, disorders. neurodegenerative and psychiatric disorders, and gastrointestinal disorders. The present invention further relates to pharmaceutical compositions containing such compounds and methods for preparing such compounds.

MA37836A 2012-07-17 2013-07-16 5-HT3 Receptor Antagonists MA37836B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672709P 2012-07-17 2012-07-17
PCT/US2013/050746 WO2014014951A1 (en) 2012-07-17 2013-07-16 5-ht3 receptor antagonists

Publications (2)

Publication Number Publication Date
MA37836A1 true MA37836A1 (en) 2018-03-30
MA37836B1 MA37836B1 (en) 2018-10-31

Family

ID=58530739

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37836A MA37836B1 (en) 2012-07-17 2013-07-16 5-HT3 Receptor Antagonists

Country Status (2)

Country Link
MA (1) MA37836B1 (en)
UA (1) UA113991C2 (en)

Also Published As

Publication number Publication date
UA113991C2 (en) 2017-04-10
MA37836B1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
MA43169B1 (en) Heterocyclic compounds as pi3k-gamma inhibitors
MA37762A1 (en) N-aryltriazole compounds used as antagonists of lpar
MA37764A1 (en) N-alkyltriazole compounds used as antagonists of lpar
MA40111B1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA31158B1 (en) Tricyclic compounds and their use as modifiers for glucocorticoid receptors.
EA201170624A1 (en) ISONICOTINAMIDE ANTAGONISTS OF OREXIN RECEPTORS
MA37888B1 (en) Coated pharmaceutical composition containing regorafenib
EA201390683A1 (en) PIPERIDINONCARBOXAMIDAZAZINDANES - CGRP RECEPTOR ANTAGONISTS
MA30232B1 (en) HYDANTOIN BASED KINASE INHIBITORS
IN2015DN00957A (en)
MA45598B1 (en) 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
MA40955A (en) 2-AMINO-6- (DIFLUOROMETHYL) -5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
WO2019007696A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
MA35271B1 (en) Antagonists of trpm8 and their use in treatments
MA34545B1 (en) CO-CRYSTALS AND SALTS OF CCR3 INHIBITORS
MA34968B1 (en) ASYMMETRIC UREA AND MEDICAL USES THEREOF
MA37439A1 (en) Cyclic ether bridge dgat1 inhibitors for the treatment of acyl mediated disorders coa-diacylglycerol transferase 1 (dgat1).
MA37765A1 (en) Substituted pyrazole compounds used as lpar antagonists
MA42776B1 (en) Compounds useful for inhibiting t-ror
MA39253B1 (en) Substituted bicyclic heteroaryl compounds used as rxr agonists
MA43913B1 (en) Positive allosteric modulators of the m1 muscarinic receptor
MA38250B1 (en) New hydantoin derivatives for their uses in the treatment of diseases, such as osteoporosis and thrombocytopenia
MA37836A1 (en) 5-HT3 Receptor Antagonists
EA201290532A1 (en) BICYCLIC THIAZOLES AS AN ALLYSTERIC MODULATORS OF MGLUR5 RECEPTORS
MA37879B1 (en) Stabilized amorphous form of agomelatine, process for its preparation and pharmaceutical compositions containing it